Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB0159 in Mild to Moderate Psoriasis and Healthy Subjects
NCT07849894Phase 1Completed
- Sponsor
- UCB
- Start
- Jun 2017
- Primary completion
- Dec 2018
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in plaque psoriasis comparing UCB0159 dosing regimen with Placebo (2 arms). Primary endpoints: Number of Adverse Events at Day 85, Maximum serum concentration and 2 more. Started Jun 2017; status: completed.
02
Drugs
UCB0159
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07849894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07849894.